Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors

Activating mutations in PIK3CA are frequent in human breast cancer, and phosphoinositide 3-kinase alpha (PI3Kα) inhibitors have been approved for therapy. To characterize determinants of sensitivity to these agents, we analyzed PIK3CA-mutant cancer genomes and observed the presence of multiple PIK3C...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Science
Main Authors: Vasan, Neil, Razavi, Pedram, Johnson, Jared L., Shao, Hong, Shah, Hardik, Antoine, Alesia, Ladewig, Erik, Gorelick, Alexander, Lin, Ting-Yu, Toska, Eneda, Xu, Guotai, Kazmi, Abiha, Chang, Matthew T., Taylor, Barry S., Dickler, Maura N., Jhaveri, Komal, Chandarlapaty, Sarat, Rabadan, Raul, Reznik, Ed, Smith, Melissa L., Sebra, Robert, Schimmoller, Frauke, Wilson, Timothy R., Friedman, Lori S., Cantley, Lewis C., Scaltriti, Maurizio, Baselga, José
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7173400/
https://ncbi.nlm.nih.gov/pubmed/31699932
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/science.aaw9032
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados